July 26, 2016 8:31 AM ET


Company Overview of Eurofarma Laboratórios S.A.

Company Overview

Eurofarma Laboratórios S.A. produces and markets medical prescription, veterinary, and over-the-counter drugs. It also offers medicines for hospital use, which include antibiotics, anesthetics, antifungals, antivirals, uterine stimulants, exchange resins, anti-ulcer, anti-inflammatory, and anticoagulant drugs; and serums in bags and jars. In addition, the company provides antiparasitic, vitamins, and tonics for the prevention and treatment of diseases primarily in cattle; and oncology drugs. Further, it manufactures medicines of various therapeutic classes and in various dosage forms, including cosmetics and hygiene products to other laboratories. Further, the company offers ampoules and via...

Av. Vereador José Diniz, nº 3465

Campo Belo

São Paulo, SP 04603-003


Founded in 1972


55 11 5090 8600


55 11 5090 8742

Key Executives for Eurofarma Laboratórios S.A.

Eurofarma Laboratórios S.A. does not have any Key Executives recorded.

Eurofarma Laboratórios S.A. Key Developments

Eurofarma Laboratórios S.A. Presents at BIO-Europe 2015, Nov-02-2015

Eurofarma Laboratórios S.A. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

Ceyoka (Pvt) Ltd. Signs Distributor Pact with Eurofarma

Ceyoka (Pvt) Ltd. signed a milestone exclusive distributor agreement with Eurofarma. Under the terms of the exclusive agreement (oncological products), Ceyoka has received the sole legal rights from Eurofarma to import, stock, promote, market and distribute its range of pharmaceuticals in Sri Lanka. The landmark agreement with Ceyoka, signals the first foray by a Brazil based multinational pharmaceutical company in to the country. Ceyoka retains the exclusive right in Sri Lank to promote and distribute products under the Eurofarma trade mark.

Melinta Therapeutics, Inc. Partners with Eurofarma Laboratorios S.A

Melinta Therapeutics, Inc. and Eurofarma Laboratorios S.A. have entered into commercialization and distribution agreements for delafloxacin, an investigational fluoroquinolone. Under the terms of the agreements, Eurofarma will be responsible for obtaining regulatory approval in Brazil and will then have the right to market, sell and distribute delafloxacin in that country for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta will receive a combined upfront cash and equity payment of $15 million, as well as milestones and royalties on future sales of delafloxacin.

Similar Private Companies By Industry

Company Name Region
A Química Santa Marina S/A Americas
Aché Laboratórios Farmacêuticos S.A. Americas
Allegê Laboratórios Americas
Alvos Americas
Anidro do Brasil Extrações S.A. Americas

Recent Private Companies Transactions

September 17, 2015
Sanofi, Factory in Argentina

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Eurofarma Laboratórios S.A., please visit www.eurofarma.com.br. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.